Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Commercial Officer Bryan Riggsbee - Chief Financial Officer Conference Call Participants Elizabeth Koslosky - Goldman Sachs Andrew Cooper - Raymond James Daniel Sammarco - TD Cowen Jack Meehan - Nephron Research Wolf Chanoff - Bank of America Matt Scalo Good aftern ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Bryan Riggsbee - Chief Financial Officer Nicole Lambert - Chief Operating Officer Mark Verratti - Chief Commercial Officer Conference Call Participants Matt Sykes - Goldman Sachs Andrew Cooper - Raymond James Jack Meehan - Nephron Research Operator Greetings, and welcome to the Myriad Geneti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Start Time: 16:30 January 1, 0000 5:18 PM ET Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2023 Earnings Conference Call May 03, 2023, 16:30 PM ET Company Participants Paul Diaz - President and CEO Nicole Lambert - COO Bryan Riggsbee - CFO Mark Verratti - Chief Commercial Officer. Matthew Scalo - SVP, IR Conference Call Participants Andrew Cooper - Raymond James Dave Delahunt - Goldman Sachs John Kim - Bank of America Jack Meehan - Nephron Research Puneet Souda - SVB Jacob Krahenbuhl - Stephens Matthew Scalo Okay. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O ...

Raymond James 2023 Institutional Investors Conference March 6, 2023 ©2023Myriad Genetics, Inc. All rights reserv™ed. ©2023Myriad Genetics, Inc. All rights reserved. www.Myriad.com Forward-looking statements and Non-GAAP financial measures Some of the information These statements are based on management’s current expectations and the actual presented here today may events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Mark Verratti - Chief Commercial Officer. Conference Call Participants Tom Stevens - Cowen and Company Jack Meehan - Nephron Research Operator Greetings, and welcome to the Myriad Genetics Fourth Quarter 2022 Financial Earnings Conference Call. During the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |------------------------------------------------------------ ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Conference Call Participants Daniel Brennan - Life Science & Diagnostic Tools Matthew Sykes - Goldman Sachs Jack Meehan - Nephron Research Mason Carrico - Stephens Incorporated Brandon Couillard - Jefferies Julia Kim - JPMorgan Puneet Souda - SVB Securities ...